Urologicum Duisburg
- Address
- lock Available on a paid plan
Prostate Cancer Research
At Urologicum Duisburg, a major focus is male urogenital diseases, especially prostate cancer and its advanced forms. The studies are designed to test new treatment approaches, refine hormone-based care, and improve outcomes for men with recurrent, metastatic, or high-risk disease.
- Metastatic castration-resistant and castration-sensitive prostate cancer
- Biochemically recurrent and high-risk prostate cancer after surgery
- Improving survival, delaying progression, and reducing recurrence
Several trials also explore whether combining androgen deprivation therapy with newer targeted or immune-based treatments can provide better disease control.
Bladder Cancer and Urothelial Tumor Studies
This site is active in urinary bladder neoplasms and non-muscle invasive bladder cancer, with research aimed at improving local and systemic treatment options. The trials are focused on helping patients with early-stage, high-risk, or treatment-resistant disease.
- Non-muscle invasive bladder cancer and high-risk NMIBC
- Urothelial carcinoma and other bladder tumors
- Testing new combinations to increase response rates and prevent recurrence
Research at the site includes studies that compare established bladder cancer care with newer therapies intended to strengthen disease-free survival and complete response.
Advanced Urologic Cancer Treatment Innovation
The clinical trial portfolio also covers neoplasms with a strong emphasis on advanced cancer care, including studies for patients whose disease has spread or become resistant to standard treatment. These trials aim to evaluate whether novel medicines can improve survival and slow cancer progression.
- Advanced and metastatic urogenital cancers
- Comparing new therapies with current standards of care
- Measuring outcomes such as progression-free survival and overall survival
Across these studies, the research at Urologicum Duisburg reflects a broader effort to expand treatment choices for difficult-to-treat cancers of the urinary and reproductive system.
Supportive Symptoms and Quality of Life Research
In addition to cancer-focused work, the site is involved in studies addressing symptoms and daily functioning within reproductive and urinary physiological processes. These trials look beyond tumor control to improve comfort, sleep, and quality of life for patients living with chronic conditions.
- Insomnia disorder with comorbid nocturia
- Improving sleep and urinary symptom management
- Assessing whether symptom-targeted treatment can ease everyday burden
This area of research shows the site’s interest in both disease treatment and the practical challenges patients face during care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 10 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Janssen Cilag International1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Urologicum Duisburg
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (21492 ARASTEP) A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared with placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer | Bayer AG, Bayer Consumer Care AG | Phase III | Not Recruiting | Oct 2023 | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abiraterone Acetate | 3 | Unknown | 2020-09-18 | 2026-03-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.